LTR PHARMA LIMITED — Capital/Financing Update 2024

Jul 30, 2024

==> picture [594 x 63] intentionally omitted <==

Cleansing Notice under Section 708A of the Corporations Act

31 July 2024

LTR Pharma Limited ( ASX:LTP ) (“ LTR Pharma ”, “the Company ”), a company focused on improving men’s health through the clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction, SPONTAN[®] , gives notice under section 708(A)(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) regarding the issue of 14,383,562 fully paid ordinary shares (Shares) as detailed in the Appendix 2A released to the ASX.

The Company states the following:

• 1. The Shares were issued on 31 July 2024 without disclosure to investors under part 6D.2 of the Corporations Act;
• 1. As at the date of this notice, the Company has complied with:

  • a. The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

  • b. Sections 674 and 674A of the Corporations Act; and

• 1. As at the date of this notice, there is no excluded information for the purposes of sections 708A(7) and 708A(8) of the Corporations Act.

– ENDS –

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men

==> picture [594 x 63] intentionally omitted <==

that can negatively impact self-esteem and relationships across multiple age brackets. LTR Pharma’s lead product, SPONTAN®, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body, supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

For further information, please contact:

Haley Chartres Media Relations haley@hck.digital

Peter McLennan Investor Relations investors@ltrpharma.com

==> picture [595 x 79] intentionally omitted <==